Giving babies the best start for the rest of their lives...

NEOLEV2 Efficacy of Intravenous Levetiracitam in the Treatment of Neonatal Seizures / NEOLEV2


This study hopes to improve treatment of neonatal seizures in this vulnerable and under researched population. Levetiracetam (LEV or trade name Keppra) is a very promising new treatment for neonatal seizures. Current treatments are poorly effective and have significant side effects. We have used this medicine in oral form in older children for over a decade, but the IV form has only recently become available.


The study will compare effects of LEV vs phenobarbital (the traditional treatment for neonatal seizures), obtain essential safety & efficacy data, and develop remote EEG monitoring systems that will facilitate rapid seizure detection for quicker treatment. 

What if I have more questions?

The Research Team will be contacting you regarding your interest in this study. 

You may also contact the Sharp Mary Birch Neonatal Intensive Care Unit (NICU) at: 858 939-4298, or NICU Research Offices at:  858 939-4112

To contact e-mail: